Small-cell carcinoma (SCC) is a group of highly malignant neuroendocrine tumors that are most commonly associated with the lungs, where they are referred to as small-cell lung carcinoma (SCLC). These neoplasms are characterized by small, round to fusiform cells with scant cytoplasm, finely granular chromatin, and frequent mitoses. Although the lung is the predominant site, small-cell carcinoma can arise in extrapulmonary locations, including the gastrointestinal tract, prostate, cervix, and other sites.
Classification and Related Entities
- Small-cell lung carcinoma (SCLC): Classified by the World Health Organization (WHO) as a neuroendocrine tumor of the lung, further subdivided into limited-stage and extensive-stage disease based on spread.
- Extrapulmonary small-cell carcinoma: Rare tumors sharing histologic and immunophenotypic features with SCLC but arising outside the thorax.
Epidemiology
- SCLC accounts for approximately 10–15 % of all lung cancers worldwide.
- The incidence is strongly linked to tobacco smoking; over 90 % of cases occur in current or former smokers.
- Extrapulmonary small-cell carcinoma constitutes less than 5 % of all small-cell carcinomas.
Pathogenesis
- Molecular studies frequently demonstrate alterations in tumor suppressor genes TP53 and RB1.
- Neuroendocrine differentiation is confirmed by expression of markers such as synaptophysin, chromogranin A, and CD56.
- Smoking‑related carcinogens induce DNA damage that contributes to tumor initiation.
Clinical Presentation
- Pulmonary SCC: Rapidly progressive cough, dyspnea, chest pain, weight loss, and paraneoplastic syndromes (e.g., SIADH, ectopic ACTH production).
- Extrapulmonary SCC: Symptoms vary by organ of origin but often include pain, obstructive phenomena, and systemic manifestations.
Diagnosis
- Imaging: Chest radiography and computed tomography (CT) identify primary lung lesions and mediastinal involvement; positron emission tomography (PET) assesses metabolic activity and distant spread.
- Histopathology: Core needle or bronchoscopic biopsies reveal characteristic small cells with high nuclear‑to‑cytoplasmic ratios and nuclear molding.
- Immunohistochemistry: Positive staining for neuroendocrine markers (synaptophysin, chromogranin A, CD56) aids in differentiation from non‑small cell lung carcinoma.
- Staging: The Veterans Administration Lung Study Group (VALSG) system categorizes disease as limited-stage (confined to one hemithorax) or extensive-stage (beyond one hemithorax or distant metastasis). The TNM classification is also applied in some settings.
Management
- Limited-stage disease: Combined modality therapy consisting of platinum-based chemotherapy (cisplatin or carboplatin) plus etoposide, concurrent thoracic radiation, and prophylactic cranial irradiation (PCI) for selected patients.
- Extensive-stage disease: Systemic chemotherapy remains the cornerstone; recent trials incorporate immune checkpoint inhibitors (e.g., atezolizumab, durvalumab) combined with chemotherapy.
- Surgery: Generally not indicated due to early dissemination, except in highly selected early-stage tumors.
- Supportive care addresses paraneoplastic syndromes, symptom relief, and quality of life.
Prognosis
- SCLC has a poor overall prognosis, with median survival of 15–20 months for limited-stage disease and 8–10 months for extensive-stage disease, despite aggressive therapy.
- Five‑year survival rates range from 20–30 % (limited) to less than 5 % (extensive).
- Prognostic factors include performance status, disease stage, age, and response to initial chemotherapy.
Research and Emerging Therapies
- Ongoing clinical trials evaluate novel agents targeting DNA damage response pathways, angiogenesis, and additional immune checkpoints.
- Molecular profiling aims to identify sub‑populations that may benefit from targeted therapies.
References
- WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 5th edition.
- National Comprehensive Cancer Network (NCCN) Guidelines: Small Cell Lung Cancer, Version 4.2024.
- Recent peer‑reviewed literature on immunotherapy combinations for extensive-stage SCLC (e.g., Lancet Oncology, 2023).